This is illustrated by the recent expansion of the use of immunotherapies such as immune checkpoint inhibitors (CTLA-4, PD-1 and PD-L1), which harness the host immune system to generate powerful anti-cancer effects (3). This evidence concerns the gene CD274 and cancer.